Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
3 K& b0 q% X+ `- R: R
' X& G- F$ V2 i2 y
7 J9 _6 ] L0 nSub-category:& Z& \+ x G. T6 J8 L4 Z( X
Molecular Targets
6 G9 n; ?! o- I' h f5 Z9 u7 C: V4 G3 Z6 B' ?- g
6 [0 L J. l& Z( O! ?, }+ X/ ^- C9 Q
Category:
/ U* R& U: Y- ^- A0 a2 WTumor Biology
& x1 B9 T: M7 ]! \1 |1 f A( V0 n7 g
2 ]+ v( u% A- t" u( S. Y: y
" u, k: @8 I2 yMeeting:
* p: e. v3 u" M2 G2011 ASCO Annual Meeting
7 w4 M+ E8 N3 X/ p" p- A+ Y
; [" h" P7 P( ?, G' O6 T& `/ e; J1 G1 x( l- q& L, R8 t3 x
Session Type and Session Title:; V7 r' f4 c! L4 m. U
Poster Discussion Session, Tumor Biology
G! |# q$ o5 i3 [' q+ Z& }, c4 y+ I' |, u# v$ F k
1 _" h' o3 ?9 c( h: xAbstract No:
+ E' Q; T% n7 ^# W10517 / q9 R3 l# g U1 C& s
N2 ~# h& L5 D
( c* ~, S) ?! c! _* N9 @2 n
Citation:
) e8 L5 n H/ LJ Clin Oncol 29: 2011 (suppl; abstr 10517)
( F$ p3 e7 ?& t8 ^- A2 u4 R3 a+ A
# b, C j/ w& j0 A, i8 Q2 y% }3 {$ _5 C2 x; Q R5 b
Author(s):
/ O8 Q5 `% e/ `# ~4 oJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
8 l2 V, y. U4 d$ z9 v# g, m {9 {' @: w; I* w' a
$ @5 ^2 C1 e' I, u1 I$ R$ M3 _# {
% }: m ~ E8 a; p) B1 i. z; eAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
& S- Q0 A/ Q- X4 }! U, `# o3 m) J/ L8 Y7 ?2 i6 Y
Abstract Disclosures
: o9 v- a' { @( J
3 K! m% I5 [" O MAbstract:+ c0 M# ^$ r- c2 l
. b V" j$ r' U, B
7 U# W" Z" e6 T6 I1 H3 u1 o
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
) g! t+ N) @3 B g, x
1 y: F/ y c- F. C( Q5 D2 E! s 6 K$ i$ ]* ^5 H7 Z: m+ {) ?/ `- e, x
|